Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2009

View Archived Issues

Novel GABA(A) modulator shows antinociceptive activity in vivo

Biodel to submit NDA for VIAject to FDA for diabetes

Studies with SAR-150640 show potential importance of ADRB3 agonists in preventing preterm labor

Studies determine optimal doses of sublingual immunotherapy with rBet v 1

Combination of paclitaxel and cyclophosphamide is safe in patients with bladder cancer

DSMB recommends continuation of Anthera's phase II IMPACTS clinical trial of A-001

Teva to use Compugen biomarkers for detection of drug-induced kidney toxicity

AVEO and Biogen sign definitive agreement for ErbB3-targeted antibodies

Gilead initiates phase II cicletanine trial for pulmonary arterial hypertension

FDA approves new indication for Wyeth's Tygacil

Novel orally bioavailable alkyl amines display in vivo renin inhibitory activity

Fablyn approved in Europe for the treatment of osteoporosis

Clinical study shows potential of kisspeptin-54 as a treatment for infertility

CV Therapeutics develops candidate SCD inhibitor for obesity, metabolic syndrome and diabetes

Novel IGF-1R inhibitor BMS-754807 in phase I development

CFFT grants Alnara exclusive worldwide rights to PERT therapy liprotamase

Nerviano Medical Sciences claims substituted indazole derivatives as kinase inhibitors

Oncolytics completes patient enrollment in REO 009 clinical trial of Reolysin and Gemzar

Novel pyrazoloquinoline and pyrazolonaphthyridine derivatives claimed by Novartis

HGS and Morphotek sign collaboration agreement for therapeutic monoclonal antibodies

Novartis claims novel parathyroid calcium-sensing receptor antagonists

NovaBay and Galderma sign global agreement to develop and commercialize Aganocide

Abilify oral solution 0.1% to be launched in Japan in April

Novel alpha-alkyl substituted N-acyltryptophanols discovered by Bayer Schering Pharma

Additional indication for Actos approved in Japan

Eisai claims novel polycyclic compounds against beta-amyloid load

Vertex commences phase II development for VX-809 in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.